Clinical Trial Update: Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP [Phase 3]

View source ↗

Summary

Phase 3 trial of ALXN1850 in treatment-naïve pediatric participants with hypophosphatasia is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatasia

Drugs mentioned

• ALXN1850 (ALXN1850)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hypophosphatasia | Phase 3 | Status: ACTIVE_NOT_RECRUITING